-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$35.7592.1% Upside
Capricor Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Capricor Therapeutics, Inc.?
Capricor Therapeutics, Inc. has been rated by research analysts at Piper Sandler, Oppenheimer, Maxim Group, H.C. Wainwright in the past 90 days.